Definium Therapeutics, Inc. (DFTX)
NASDAQ:DFTX
Want to see DFTX full AI Analyst Report?
DFTX Stock Chart & Stats
$22.68
-$0.97(-11.96%)
At close: 4:00 PM EST
$22.68
-$0.97(-11.96%)
Day’s Range― - ―
52-Week Range$6.35 - $26.25
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.71M
Market Cap
$2.57B
Enterprise Value$2.38B
Total Cash (Recent Filing)$373.42M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Aug 06, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.50
Shares Outstanding109,066,780
10 Day Avg. Volume1,918,972
30 Day Avg. Volume1,711,044
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)3.60
Price to Sales (P/S)0.00
P/FCF Ratio-9.09
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-11.51
Forecast
1Y Price Target
$43.64Price Target Upside92.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.26
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Liquidity / RunwayA $373.4M cash/investment balance provides durable funding to complete multiple Phase III readouts, prepare regulatory filings and invest in commercial readiness. This reduces near-term financing pressure, allowing program execution and strategic planning without immediate dilution risk.
Late-stage Pipeline With Regulatory RecognitionHaving several pivotal Phase III trials underway and Breakthrough Therapy status in GAD materially de-risks the clinical pathway compared with earlier programs. Successful readouts would support regulatory submissions and create sustainable commercial optionality across MDD, GAD and planned PTSD expansion.
Low Financial LeverageA debt-free capital structure gives the company financial flexibility to fund clinical development without interest burden. Low leverage reduces bankruptcy risk and supports strategic choices (timing of filings, commercial investments) as clinical milestones unfold over the medium term.
Bears Say
Pre-revenue With Accelerating LossesBeing pre-revenue with rapidly widening losses and persistently negative operating cash flow creates sustained funding needs. Over months, this increases dilution risk and constrains reinvestment unless clinical readouts advance as planned or additional capital is raised under potentially dilutive terms.
Rising Operating BaseSubstantially higher R&D and G&A spending to support Phase III and commercialization increases the fixed-cost runway required for success. If clinical outcomes are delayed or less robust, the higher cost base amplifies downside and may force strategic cutbacks or urgent financing at unfavorable terms.
Trial Design, Placebo & Regulatory/Payer RiskA documented high placebo response and design nuances create structural risk that Phase III may fail to reproduce clear efficacy, complicating FDA assessment. Even with approval, unresolved payer coding and reimbursement pathways could materially limit commercial uptake and revenue realization.
Definium Therapeutics News
DFTX FAQ
What was Definium Therapeutics, Inc.’s price range in the past 12 months?
Definium Therapeutics, Inc. lowest stock price was $6.34 and its highest was $26.25 in the past 12 months.
What is Definium Therapeutics, Inc.’s market cap?
Definium Therapeutics, Inc.’s market cap is $2.57B.
When is Definium Therapeutics, Inc.’s upcoming earnings report date?
Definium Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 61 days.
How were Definium Therapeutics, Inc.’s earnings last quarter?
Definium Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.492 by -$0.218.
Is Definium Therapeutics, Inc. overvalued?
According to Wall Street analysts Definium Therapeutics, Inc.’s price is currently Undervalued.
Does Definium Therapeutics, Inc. pay dividends?
Definium Therapeutics, Inc. does not currently pay dividends.
What is Definium Therapeutics, Inc.’s EPS estimate?
Definium Therapeutics, Inc.’s EPS estimate is -0.56.
How many shares outstanding does Definium Therapeutics, Inc. have?
Definium Therapeutics, Inc. has 109,066,780 shares outstanding.
What happened to Definium Therapeutics, Inc.’s price movement after its last earnings report?
Definium Therapeutics, Inc. reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.492. Following the earnings report the stock price went down -4.957%.
Which hedge fund is a major shareholder of Definium Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DFTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Definium Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.64 (92.40% Upside)
$43.64 (92.40% Upside)
Blogger Sentiment
Bullish
DFTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
221.43%
12-Months-Change
Fundamentals
Return on Equity
-102.48%
Trailing 12-Months
Asset Growth
45.75%
Trailing 12-Months
Company Description
Definium Therapeutics, Inc.
Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
DFTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasizes strong clinical momentum (multiple Phase III programs with imminent topline readouts, Breakthrough Therapy designation in GAD, high statistical power in key studies), a clear commercialization plan and a solid cash position ($373.4M runway into 2028). These positives are tempered by materially higher operating expenses and a sizable YOY increase in net loss (driven by program investment and a non-cash warrant valuation change), design-related placebo risk from Phase II, and remaining regulatory and payer uncertainties that could affect timing and labeling. On balance, management’s message is forward-looking and execution-focused with meaningful near-term inflection points.View all DFTX earnings summariesDFTX Stock 12 Month Forecast
Average Price Target
$43.64
▲(92.40% Upside)
Technical Analysis
AnaptysBio
―
Enliven Therapeutics
―
Tyra Bioscience
―
Biohaven Ltd.
―
Inhibrx Biosciences Inc
―
Ownership Overview
1.58% Insiders
9.04% Mutual Funds
34.53% Other Institutional Investors
46.70% Public Companies and Individual Investors